ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.

Jacob Sands,Sumithra J. Mandrekar,Geoffrey R. Oxnard,David Kozono,Shauna L. Hillman,Suzanne E. Dahlberg,Zhuoxin Sun,Jamie E. Chaft,Ramaswamy Govindan,David E. Gerber,Jhanelle E. Gray,Shakun Malik,Margaret Mooney,Pasi A. Jänne,Everett E. Vokes,Karen Kelly,Suresh S. Ramalingam,Tom Stinchcombe

ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.

2020

Jacob Sands
Sumithra J. Mandrekar
Geoffrey R. Oxnard
David Kozono
Shauna L. Hillman
Suzanne E. Dahlberg
Zhuoxin Sun
Jamie E. Chaft
Ramaswamy Govindan
David E. Gerber
Jhanelle E. Gray
Shakun Malik
Margaret Mooney
Pasi A. Jänne
Everett E. Vokes
Karen Kelly
Suresh S. Ramalingam
Tom Stinchcombe

TPS9077Background: ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial) is a clinical trial platform of the National Cancer Institute that offers biomarker analysi...

Keywords:

Oncology
Adjuvant
Immunotherapy
Targeted therapy
Pathology
Internal medicine
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations